Angiosarcoma of Bone — a rare, aggressive malignant vascular tumor originating from endothelial cells within the bone marrow, accounting for fewer than 1% of all primary malignant bone tumors yet exhibiting a clinical behavior that distinguishes it as one of the most challenging primary bone malignancies to manage: a propensity for multifocal presentation (synchronous involvement of multiple non-contiguous bone sites at the time of diagnosis, identified in 20–50% of cases depending on the thoroughness of whole-body staging), a high rate of metastasis to lung, liver, and lymph nodes at presentation, a median overall survival of 12–18 months for metastatic disease, and a 5-year overall survival for all comers of 20–40% — outcomes that reflect the systemic nature of a vascular tumor that can seed multiple skeletal sites and viscera simultaneously, the rarity that has prevented large prospective treatment trials, and the diagnostic challenge of distinguishing angiosarcoma from other malignant vascular tumors of bone (epithelioid hemangioendothelioma, which has a far better prognosis and must be distinguished from angiosarcoma to avoid over-treatment), metastatic sarcoma with vascular differentiation, and poorly differentiated carcinoma on small biopsy specimens. Angiosarcoma of bone presents most commonly in adults in the fifth to seventh decades with bone pain, local swelling, and pathologic fracture — most frequently arising in the long bones (femur, tibia, humerus, radius) and pelvis, with multifocal presentation characteristically affecting one extremity (e.g., multiple sites within the femur and tibia of one leg) or both extremities simultaneously; radiographically, angiosarcoma of bone produces a geographic or permeative lytic destruction pattern with cortical breakthrough and soft tissue extension, absent or minimal bone production (distinguishing it from osteosarcoma), and in multifocal cases a distinctive "multiple osteolytic lesions in one extremity" pattern that is characteristic and should prompt biopsy at the most accessible site. Pathologically, angiosarcoma of bone demonstrates infiltrating channels or nests of malignant endothelial cells with vasoformation (blood-filled vascular spaces of variable architecture from well-differentiated channel-forming to poorly differentiated solid sheets), endothelial cell cytologic atypia, mitotic activity, and necrosis; immunohistochemical expression of endothelial markers (CD31 — most sensitive; ERG — most specific nuclear marker; CD34; FLI-1; factor VIII-related antigen) is required for diagnosis; the epithelioid variant, where the endothelial cells are large and epithelioid rather than spindled, is most likely to be misdiagnosed as carcinoma or epithelioid sarcoma on limited biopsy material and requires CD31/ERG confirmation. Treatment strategy for angiosarcoma of bone integrates surgical resection for localized or oligofocal disease (wide local excision with limb-sparing reconstruction where anatomically feasible), systemic chemotherapy for metastatic or unresectable disease (taxane-based regimens — paclitaxel weekly or docetaxel — have activity specific to angiosarcoma in contrast to most other soft tissue and bone sarcomas where taxanes have limited activity, and anthracycline-based regimens such as doxorubicin with or without ifosfamide are also used), anti-angiogenic targeted therapy (pazopanib, sorafenib, and bevacizumab have demonstrated activity in vascular tumors including angiosarcoma), and consolidative radiation therapy for close or positive margins.
Angiosarcoma of bone technology platforms — whether supporting bone tumor programs performing the endothelial immunohistochemical panel (CD31, ERG, CD34, FLI-1, factor VIII) required to confirm vascular differentiation and distinguish angiosarcoma from epithelioid hemangioendothelioma and carcinoma, nuclear medicine and PET/CT platforms managing whole-body skeletal staging to identify synchronous bone sites and visceral metastases at diagnosis, medical oncology programs administering weekly paclitaxel or anthracycline-based chemotherapy, orthopedic oncology programs managing surgical resection and reconstruction for localized sites, radiation oncology programs planning consolidative radiotherapy, and targeted therapy programs managing anti-angiogenic agents and their vascular toxicity monitoring — must maintain the availability and performance standards that angiosarcoma of bone's diagnostic complexity, multifocal staging imperatives, chemotherapy monitoring demands, and aggressive clinical course require. This guide explains why angiosarcoma of bone tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the diagnostic, staging, surgical, chemotherapy, and targeted therapy complexity of modern angiosarcoma of bone management.
Why Angiosarcoma of Bone Tech Platforms Require Specialized Monitoring Attention
Angiosarcoma of bone management is defined by the diagnostic imperative of confirming endothelial differentiation by immunohistochemistry in a tumor that mimics carcinoma and other sarcomas on morphology alone, the staging imperative of whole-body skeletal survey and PET/CT to identify the 20–50% of patients with multifocal or metastatic disease at diagnosis before planning potentially futile local resection, the treatment-selection challenge of choosing between taxane-based regimens (with angiosarcoma-specific activity) and anthracycline-based regimens for systemic disease, the anti-angiogenic toxicity monitoring requirement (hypertension, thromboembolism, wound healing impairment, hemorrhage) for targeted therapy agents, and the surgical precision of wide local excision and limb-sparing reconstruction for the subset with resectable localized disease. Technology failures in these domains create disruptions calibrated to the diagnostic, staging, and treatment consequences of a rare aggressive vascular bone malignancy where initial management decisions made within the first 4–8 weeks of diagnosis substantially determine whether the patient is treated with curative or palliative intent.
Bone tumor pathology and vascular immunohistochemistry platforms are central to diagnosis. CD31, ERG, CD34, FLI-1, and factor VIII-related antigen immunohistochemistry on core needle biopsy material — alongside exclusion of carcinoma markers and epithelioid hemangioendothelioma versus angiosarcoma grade distinction — require reliable diagnostics platform availability during business hours. Monitor diagnostics platforms at 1-minute intervals during business hours.
PET/CT and bone scan staging platforms determine treatment intent. Whole-body FDG PET/CT and technetium bone scan to identify synchronous bone involvement and visceral metastases — findings present in 20–50% of angiosarcoma of bone patients at diagnosis that convert curative surgical planning to palliative systemic treatment — require platform availability at initial staging. Monitor staging platforms during imaging and reporting sessions.
Medical oncology platforms manage taxane or anthracycline chemotherapy. Weekly paclitaxel with myelosuppression and peripheral neuropathy monitoring, or doxorubicin with ifosfamide with leucovorin rescue and cardiotoxicity monitoring, require time-critical platform availability for cycle scheduling, toxicity assessment, and dose modification during infusion. Monitor oncology platforms during infusion sessions.
Targeted therapy platforms manage anti-angiogenic agents and vascular toxicity. Pazopanib, sorafenib, or bevacizumab administration with blood pressure monitoring (hypertension in 40–70% of patients on VEGF pathway inhibitors), thromboembolism assessment, wound healing monitoring for surgical site integrity, and hemorrhage surveillance require frequent monitoring platform availability. Monitor targeted therapy platforms during clinical encounters.
Radiation oncology platforms deliver consolidative radiation. IMRT or VMAT for close or positive margins after bone resection for angiosarcoma requires treatment planning with organs-at-risk contouring adjacent to spinal cord, lung, or bowel depending on the primary site. Monitor radiation platforms during clinical and treatment hours.
What to Monitor on an Angiosarcoma of Bone Tech Platform
Bone Tumor Pathology and Vascular Endothelial Immunohistochemistry
Monitor angiosarcoma of bone core needle biopsy histomorphologic assessment records (vasoformation architecture — well-differentiated channel-forming versus poorly differentiated solid sheets; endothelial atypia grade; mitotic index; necrosis), vascular endothelial immunohistochemical panel records (CD31 — most sensitive vascular marker; ERG — nuclear endothelial transcription factor; CD34; FLI-1; factor VIII-related antigen), epithelioid variant carcinoma exclusion panel records (AE1/AE3, CAM5.2, MOC31, Ber-EP4 for carcinoma exclusion), epithelioid hemangioendothelioma distinction documentation (WWTR1-CAMTA1 fusion FISH or immunohistochemistry for hemangioendothelioma confirmation), grade determination records, Ki-67 proliferation index, multidisciplinary tumor board vascular tumor pathology review, and second-opinion consultation documentation at referral centers for rare vascular bone tumor expertise at 1-minute intervals during business hours. Alert immediately — pathology platform failures delay CD31/ERG immunohistochemical confirmation in cases where the distinction between high-grade angiosarcoma (requiring aggressive systemic treatment) and epithelioid hemangioendothelioma (carrying a far better prognosis requiring less aggressive management) determines the urgency of systemic treatment initiation.
Whole-Body Staging and PET/CT Imaging
Monitor FDG PET/CT whole-body staging acquisition and reporting records (skull base to mid-thigh, with skull and extremities for multifocal bone survey), technetium-99m bone scan records for additional skeletal sensitivity (skeletal metastasis identification), CT chest/abdomen/pelvis records for visceral metastasis and lymph node assessment, whole-body MRI records for bone marrow infiltration assessment (particularly for multifocal long-bone angiosarcoma), primary bone lesion MRI records for soft tissue extension and neurovascular proximity assessment (preoperative planning for resectable localized cases), and multidisciplinary tumor board staging review documentation at 1-minute intervals during imaging and reporting sessions. Alert immediately — staging platform failures delay the whole-body PET/CT that identifies the 20–50% of patients with multifocal or metastatic disease at diagnosis before a surgical team begins operative planning for a potentially futile single-site resection.
Medical Oncology and Taxane or Anthracycline Chemotherapy
Monitor weekly paclitaxel administration records (dose calculation, pre-medication with dexamethasone, diphenhydramine, and H2 antagonist, infusion reaction monitoring, peripheral neuropathy assessment and neurotoxicity grading, myelosuppression monitoring), docetaxel administration records and fluid retention management documentation, doxorubicin and ifosfamide administration records for anthracycline-based regimens (ifosfamide mesna uroprotection scheduling, doxorubicin cumulative dose tracking, echocardiographic cardiotoxicity surveillance), gemcitabine and docetaxel combination records for second-line settings, complete blood count and dose modification documentation for myelosuppression, cycle scheduling and chemotherapy response assessment documentation, and RECIST or modified WHO response criteria application to imaging at planned reassessment timepoints at 1-minute intervals during infusion sessions. Alert immediately — paclitaxel infusion platform failures during active infusion reaction monitoring (severe hypersensitivity reactions occur in 1–2% of paclitaxel infusions despite pre-medication) require immediate access to epinephrine administration protocols and infusion hold documentation.
Anti-Angiogenic Targeted Therapy and Vascular Toxicity Monitoring
Monitor pazopanib, sorafenib, or bevacizumab administration records (oral vs. IV route documentation), blood pressure monitoring records (VEGF pathway inhibitor hypertension requiring anti-hypertensive dose adjustment in 40–70% of patients), thromboembolic event assessment and anticoagulation management records (DVT, PE, and arterial thrombosis on anti-angiogenic therapy), surgical wound healing and fistula surveillance records (bevacizumab wound dehiscence risk requires a minimum 28-day surgical wound healing interval before initiation), hemorrhage risk monitoring records (tumor-associated hemorrhage, epistaxis, hemoptysis, GI bleeding), hand-foot skin reaction grading and dose modification records for sorafenib, hepatotoxicity monitoring records for pazopanib (liver function tests every 4 weeks), and treatment response imaging records at 1-minute intervals during clinical encounter hours. Alert immediately — targeted therapy platform failures during blood pressure monitoring for a patient on pazopanib with known VEGF inhibitor hypertension delay anti-hypertensive dose adjustment that is clinically urgent when blood pressure exceeds 160/100 mmHg at a clinic visit.
Orthopedic Oncology and Surgical Resection for Localized Disease
Monitor primary bone angiosarcoma surgical planning records for resectable localized disease (preoperative CT for cortical involvement and soft tissue extension mapping, MRI for neurovascular proximity, preoperative resection planning for wide local excision margins in a vascular tumor where hemorrhage and soft tissue planes may be altered), wide local excision operative records (margin documentation, intraoperative blood loss management for a highly vascular tumor, neurovascular structure preservation documentation), limb-sparing reconstruction records (endoprosthetic reconstruction, intercalary allograft, or arthrodesis depending on site), pathologic fracture stabilization records for fractured angiosarcoma lesions, post-resection margin assessment and re-resection planning documentation, and rehabilitation records at 1-minute intervals during operative sessions. Alert immediately — surgical planning platform failures during the final preoperative planning session for a wide local excision of a proximal humeral angiosarcoma — where the orthopedic oncologist reviewing the MRI must confirm the relationship of the brachial artery and brachial plexus cords to the posterior tumor margin before committing to the posterior approach — eliminate access to the imaging on which safe resection of a highly vascular tumor adjacent to critical neurovascular structures depends.
Radiation Oncology and Consolidative Radiotherapy
Monitor CT simulation records for angiosarcoma of bone post-resection IMRT planning, treatment volume delineation records (tumor bed and margin extension in a vascular tumor with ill-defined margins on post-operative imaging), organs-at-risk contouring documentation, IMRT or VMAT plan optimization records, daily image-guided radiation therapy delivery records, acute wound healing monitoring during radiation (angiosarcoma-associated skin and soft tissue healing impairment), and radiation oncology tumor board review records during clinical and treatment hours. Alert on sustained failures — radiation delivery platform failures during active treatment for a patient with close surgical margins who relies on IMRT consolidation disrupt the treatment window for local control.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Angiosarcoma of bone programs coordinate across bone tumor pathology with vascular immunohistochemistry, nuclear medicine for whole-body PET/CT staging, medical oncology for taxane or anthracycline chemotherapy and anti-angiogenic targeted therapy, orthopedic oncology for surgical resection, radiation oncology for consolidative IMRT, and palliative medicine for symptom management in the subset with aggressive metastatic disease — authentication failures simultaneously block every clinician whose access to vascular IHC reports, staging imaging, chemotherapy records, surgical plans, and treatment monitoring is required for coordinated management of a rare aggressive vascular bone tumor.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, pathology reporting platforms, PET/CT imaging systems, chemotherapy management platforms, targeted therapy monitoring systems, radiation treatment planning systems, and surgical planning platforms. Certificate errors disrupt the vascular tumor diagnostic reporting, staging imaging, chemotherapy management, targeted therapy monitoring, and radiation delivery workflows of angiosarcoma of bone management.
HIPAA and Oncology Data Privacy Considerations
Angiosarcoma of bone technology platforms handle sensitive PHI including vascular endothelial immunohistochemical panel records, whole-body FDG PET/CT and bone scan staging records with multifocal skeletal disease documentation, taxane and anthracycline chemotherapy administration records with peripheral neuropathy and cardiotoxicity surveillance, anti-angiogenic targeted therapy records with blood pressure and thromboembolic event monitoring, surgical resection operative documentation for a highly vascular tumor, and consolidative radiation treatment records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing whole-body PET/CT records that document the presence or absence of multifocal bone involvement and visceral metastasis — findings that convert curative to palliative treatment intent and carry profound prognostic significance — integrity and availability standards must reflect the clinical weight of this staging PHI. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for bone tumor and sarcoma programs managing the intersection of vascular tumor diagnostics, staging imaging, chemotherapy, targeted therapy, surgical, and radiation PHI.
Alerting Strategy for Angiosarcoma of Bone Tech Platforms
Immediate alerting during chemotherapy infusion: Weekly paclitaxel with infusion reaction monitoring, doxorubicin and ifosfamide with mesna and cardiotoxicity surveillance, and anti-angiogenic targeted therapy blood pressure monitoring during infusion or clinical encounters. Paclitaxel hypersensitivity reaction management is time-critical.
Immediate alerting during operative sessions: Orthopedic oncology surgical planning for wide local excision of a vascular bone tumor with hemorrhage risk, intraoperative blood loss documentation, and limb-sparing reconstruction operative records.
Immediate alerting during staging imaging windows: Whole-body FDG PET/CT and bone scan acquisition and reporting at initial staging — findings that determine treatment intent (curative vs. palliative) for the 20–50% of patients with multifocal or metastatic disease.
Immediate business-hours alert: CD31/ERG vascular immunohistochemistry and epithelioid hemangioendothelioma versus angiosarcoma distinction pathology reporting platforms.
Sustained-failure alert (10–15 minutes): Post-treatment surveillance PET/CT scheduling, anti-angiogenic toxicity monitoring during oral targeted therapy, and recurrence tumor board review platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms angiosarcoma of bone platform availability from the geographies where high-volume bone tumor programs with vascular tumor pathology expertise and sarcoma-specific chemotherapy experience concentrate.
Status Page for Angiosarcoma of Bone Care Team Communication
A real-time status page gives bone tumor pathologists issuing CD31/ERG reports, nuclear medicine physicians interpreting whole-body staging PET/CT for multifocal bone involvement, medical oncologists managing weekly paclitaxel infusion reaction monitoring, orthopedic oncologists planning wide local excision of a hemorrhagic proximal femoral angiosarcoma, radiation oncologists planning IMRT for a close margin, and palliative medicine consultants documenting symptom management for aggressive metastatic disease immediate platform visibility without requiring inbound IT support contact. During a staging imaging platform outage when a newly diagnosed angiosarcoma of bone patient is scheduled for whole-body PET/CT that will determine whether surgical planning for a solitary tibial lesion proceeds or is deferred in favor of systemic chemotherapy, a status page enables immediate contingency rescheduling.
Include the status page URL in sarcoma chemotherapy infusion emergency protocols, PET/CT staging contingency procedures, bone tumor pathology emergency access procedures, and IMRT radiation delivery downtime procedures.
Vigilmon Setup for Angiosarcoma of Bone Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | CD31 / ERG vascular IHC / EHE vs angiosarcoma pathology | 1 min | Slack + PagerDuty (business hours) | | Whole-body PET/CT and bone scan staging | 1 min | Slack + PagerDuty (imaging hours) | | Weekly paclitaxel / infusion reaction monitoring | 1 min | Slack + PagerDuty (infusion hours) | | Doxorubicin / ifosfamide / mesna administration | 1 min | Slack + PagerDuty (infusion hours) | | Anti-angiogenic targeted therapy / blood pressure monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Radiation IMRT delivery / image-guided treatment | 1 min | Slack + PagerDuty (treatment hours) | | Orthopedic oncology surgical planning / resection | 1 min | Slack + PagerDuty (surgical hours) | | Post-treatment PET/CT surveillance scheduling | 2 min | Slack (business hours) | | Anti-angiogenic toxicity monitoring (oral outpatient) | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure CD31/ERG vascular immunohistochemistry and EHE-versus-angiosarcoma pathology platforms with immediate business-hours alerting
- Add whole-body PET/CT and bone scan staging platforms with immediate alerting during imaging and reporting windows
- Configure weekly paclitaxel infusion reaction monitoring with immediate alerting during infusion sessions
- Add doxorubicin, ifosfamide, and mesna administration with immediate infusion-hours alerting
- Configure anti-angiogenic targeted therapy clinical monitoring with immediate alerting during clinical encounter hours
- Add IMRT radiation delivery and image-guided treatment with immediate alerting during treatment sessions
- Configure orthopedic oncology surgical planning and operative documentation with immediate surgical-hours alerting
- Add post-treatment PET/CT surveillance scheduling with sustained-failure alerting
- Configure oral anti-angiogenic targeted therapy outpatient toxicity monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, diagnostic, staging, chemotherapy, targeted therapy, radiation, and surgical domains
- Add the status page URL to sarcoma chemotherapy infusion emergency protocols, PET/CT staging contingency procedures, vascular tumor pathology emergency access procedures, and IMRT downtime procedures
Conclusion
Angiosarcoma of bone technology platforms are embedded in clinical decisions where whole-body PET/CT staging platform availability at the scheduled initial staging session for a 58-year-old presenting with a 6-cm lytic tibial lesion and biopsy-confirmed CD31/ERG-positive angiosarcoma — where the nuclear medicine physician acquires and reports the whole-body FDG PET/CT to assess whether the tibial primary is the sole site of disease or whether additional foci of increased metabolic activity are present in the ipsilateral femur, the contralateral lower extremity, the pelvis, the liver, or the mediastinal lymph nodes, findings that will either confirm localized tibia angiosarcoma amenable to wide local excision with tibial segmental resection and endoprosthetic reconstruction followed by adjuvant chemotherapy, or reveal the multifocal or metastatic disease present in up to 50% of angiosarcoma of bone patients at diagnosis that shifts management from curative surgical planning to palliative systemic weekly paclitaxel with response assessment after 3 cycles — cannot be delayed by staging platform unavailability at a moment when the orthopedic oncology team is simultaneously scheduling operative room time, ordering prosthetic implants, and planning blood product availability for a resection that would be futile if the staging imaging reveals metastatic disease; where vascular pathology platform availability during the immunohistochemical panel review on the tibial biopsy — where the bone tumor pathologist reviewing the CD31 and ERG immunostained sections from a tibial core biopsy showing infiltrating anastomosing vascular channels lined by overtly atypical endothelial cells must determine whether the diffuse strong CD31 and nuclear ERG positivity confirm high-grade angiosarcoma of bone or whether the more organoid vasoformation architecture and the milder cytologic atypia in one region warrant WWTR1-CAMTA1 FISH to exclude epithelioid hemangioendothelioma — a distinction that separates a tumor with a 5-year survival of 80% managed with conservative resection from a tumor with a 5-year survival of 25% requiring aggressive systemic chemotherapy — determines the correct treatment pathway and urgency of referral; and where weekly paclitaxel infusion platform availability during cycle 3 administration in a 63-year-old with metastatic angiosarcoma of bone involving the femur, tibia, and pulmonary metastases — where the nursing administration platform must document the dexamethasone 20 mg, diphenhydramine 50 mg, and ranitidine 50 mg pre-medication administered 30 minutes prior to paclitaxel, must monitor the patient continuously during the first 30 minutes of paclitaxel infusion and for 60 minutes after initiation for the grade ≥3 hypersensitivity reaction that would require immediate infusion cessation and epinephrine administration, and must record the peripheral neuropathy assessment performed before each weekly cycle to determine whether dose reduction from 80 mg/m² to 65 mg/m² is indicated based on grade ≥2 sensory neuropathy — cannot be disrupted by platform unavailability at the moment when continuous real-time documentation of the infusion reaction monitoring protocol is required for patient safety. A whole-body staging PET/CT platform that fails at the scheduled initial assessment before surgical planning for a potentially localized angiosarcoma of bone, a vascular IHC platform unavailable when CD31/ERG confirmation and EHE exclusion determine aggressive versus conservative management, a weekly paclitaxel infusion monitoring platform inaccessible during the hypersensitivity reaction surveillance window of the first 30 minutes of infusion — these are not IT incidents. They are clinical disruptions in the management of a rare aggressive vascular bone malignancy where staging accuracy, diagnostic precision, and chemotherapy safety monitoring are the pillars on which the achievable survival outcomes in angiosarcoma of bone — excellent for localized disease with adequate resection, poor for multifocal or metastatic disease — are built.
Uptime monitoring gives angiosarcoma of bone tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to bone tumor pathology programs, nuclear medicine departments, sarcoma medical oncology services, orthopedic oncology teams, radiation oncology departments, and compliance auditors that platform operational reliability matches the staging urgency, diagnostic precision, chemotherapy safety demands, and anti-angiogenic toxicity monitoring obligations of modern angiosarcoma of bone management.
Start monitoring your angiosarcoma of bone care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #angiosarcomaofbone #vasculartumor #bonesarcoma #CD31 #ERG #PETCT #paclitaxel #doxorubicin #antiangiogenic #pazopanib #sorafenib #bevacizumab #multifocal #IMRT #orthopedic #sarcomaoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre